Prescient Therapeutics Opens First U.S. Site for PTX-100 Phase 2a Trial in CTCL Patients.

Prescient Therapeutics Limited (ASX: PTX) has announced the initiation of its first U.S. clinical site at the prestigious VCU Massey Comprehensive Cancer Center for its Phase 2a trial of PTX-100 in relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL) patients. This milestone expands the ongoing trial beyond Australia, where four patients have already been enrolled across three sites. PTX-100 is a first-in-class GGT-1 inhibitor with FDA Orphan and Fast Track designations, showing promising safety and efficacy in earlier studies.

The company continues its mission to develop innovative personalised cancer therapies. CEO James McDonnell and Scientific Founder Professor Said Sebti emphasised the significance of this achievement in bringing PTX-100 closer to benefiting patients globally. Additional U.S. sites are expected to open soon. A live investor briefing will be held on 16th July at 2 PM AEST. Registration is open on Prescient’s investor portal.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com